Story · Medicine & Biotech

Jia Liu: The Lesson from Ivonescimab CRL on Designing Trials for Global Regulatory Approval

1 outlet · first reported by OncoDaily on

Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X: “The ivonescimab FDA letter raises important questions extending beyond PFS versus OS. Despite approximately 40% of patients being enrolled (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Jia Liu: The Lesson from Ivonescimab CRL on Designing Trials for Global Regulatory Approval

    Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X: “The ivonescimab FDA letter raises important questions extending beyond PFS versus OS. Despite approximately 40% of patients being enrolled

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.